The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease

Clinical Neuropharmacology

Volumn 23, Issue 3, 2000, Pages 143-148

  Chong, Derek J ^a   Suchowersky, Oksana ^a   Szumlanski, Carol ^c   Weinshilboum, Richard M ^c   Brant, Rolin ^a   Campbell, Norm R C ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

Catechol O methyltransferase (COMT); Diarrhea; Parkinson's disease; Pharmacogenetics; Polymorphism; Tolcapone

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; LEVODOPA; TOLCAPONE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

AGED; ANTIPARKINSON AGENTS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; DIARRHEA; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSON DISEASE;

EID: 0034084120     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200005000-00003     Document Type: Article

References (30)

1. Aminoff MJ. Parkinson's disease and other extrapyramidal disorders In: Fauci AS, Braunwald E, Isselbacher KJ, et al., eds. Harrison's Principles of Internal Medicine, 14th edition. New York: Mc-Graw-Hill Health Professions Division; 1998:2356-63.
2. Napolitano A, Cesura AM, Da Prada M. The role of monoamine oxidase and catechol-O-methyltransferase in dopaminergic neurotransmission. J Neurol Transm 1995;45(suppl):35-45.
3. Weinshilboum RM. 'Methylator status' and assessment of variation in drug metabolism. Clin Biochem 1988;21:201-10.
4. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995;34:4202-10.
5. Spielman RS, Weinshilboum RM. Genetics of red blood cell COMT activity: analysis of thermal stability and family data. Am J Med Genet 1981;10:279-90.
6. 1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov Disord 1997;12:426-7.
7. Weinshilboum RM, Otterness DM, Szumlanski CL. Methyltransferase pharmacogenetics: catechol-O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999;39:19-52.
8. Floderus Y, Ross SB, Wetterberg L. Erythrocyte catechol-O-methyltransferase activity in a Swedish population. Clin Genet 1981;19:389-92.
9. Kunugi H, Nanko S, Ueki A, et al. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease. Neurosci Lett 1997;221: 202-4.
10. Mcleod HL, Fang L, Luo X, Scott EP, Evans W. Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J Pharmacol Exp Ther 1994;270:26-9.
11. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993;43:2685-8.
12. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol 1998;55: 1089-95.
13. Waters CH, Kurth M, Bailey P, et al., and the Tolcapone Stable Study Group. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 1997;49:665-71.
14. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing-off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-8.
15. Rajput AH, Martin W, Saint-Hilaire M-H, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-71.
16. Jorga KM, Sedek G, Fotteler B, Zürcher G, Neilsen T, Aitken JW. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin Pharmacol Ther 1997;62:300-10.
17. Davis TL, Roznoski M, Burns RS. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord 1995;10:349-51.
18. Limousin P, Pollak P, Pfefen JP, Toumier-Gervason CL, Dubuis R, Perret JE. Acute administration of levodopa-bensarazide and tolcapone, a COMT inhibitor in Parkinson's disease. Clin Neuropharmacol 1995;18:258-65.
19. Doudet DJ, Chan GLY, Holden JE, Morrison KS, Wyatt RJ, Ruth TJ. Effects of Catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology 1997;36: 363-71.
20. Hauser RA, Molho E, Shale H, Pedder S, Dorflinger EE, and the Tolcapone De Novo Study Group. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Mov Disord 1998;13:643-7.
21. Nutt JG. Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S, eds. Advances in Neurology, Vol. 69. New York: Raven Press; 1996:493-6.
22. Larsen KR, Dajani EZ, Dajani NE, Dayton MT, Moore JG. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and sinemet on intestinal electrolyte and fluid transport in conscious dogs. Dig Dis Sci 1998;43:1806-13.
23. Chadwick RB, Conrad MP, McGinnis MD, Johnston-Dow L, Spurgeon SL, Kronick MN. Heterozygote and mutation detection by direct automated fluorescent DNA sequencing using a mutant Tag DNA polymerase. Biotechniques 1996;20:676-83.
24. Ruottinen HM, Ulmanen I, Gordin A, Syvänen C, Rinne UK. COMT genotypes and response to levodopa in Parkinson's disease: influence of COMT inhibition with entacapone [abstract]. Mov Disord 1998;13:120.
25. Vieira-Coelho MA, Soares-da-Silva P. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br J Pharmacol 1996;117:516-20.
26. Jorga KM. Pharmacokinetics, pharmacodynamics and tolerability of tolcapone: a review of early studies in volunteers. Neurology 1998;50(suppl 5):S31-8.
27. Martinez-Martin P, O'Brien CF. Extending levodopa action -COMT inhibition. Neurology 1998;50(suppl 6):S27-32.
28. Jorga KM, Fotteler B, Heizmann P, Zurcher G. Pharmcokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. Eur J Clin Pharm 1998;54:443-7.
29. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57:508-17.
30. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-62.